EUCTR2018-004013-41-NL进行中（未招募）1 期
Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Erasmus MC
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 18 years.
- •ECOG performance status 0 or 1 (Appendix A).
- •Histologically confirmed diagnosis of intrahepatic cholangiocarcinoma (ICC).
- •Unresectable ICC confined to the liver (<70% of the liver involved) with or without limited regional lymph node disease (portal) at initial presentation, as confirmed by HPB surgeons. Regional lymph nodes will be allowed, provided it is amenable to resection. Unresectability confirmed:
- •oRadiologically
- •oOr during surgical exploration in patients initially considered candidates for resection
- •Patient is able to undergo a laparotomy or minimal-invasive surgery for pump placement.
- •Positioning of a catheter for HAIP chemotherapy is technically feasible (see chapter 5) based on a CT with excellent arterial phase. The default site for the catheter insertion is the gastroduodenal artery (GDA). Accessory or aberrant hepatic arteries are no contraindication for catheter placement.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 15 days prior to inclusion:
- •oabsolute neutrophil count (ANC) =1.5 x 109/L
- •o platelets =100 x 109/L
- •oHB = 5.5 mmol/L
- •oTotal bilirubin = 1.5 UNL
- •oASAT = 5 x UNL
- •oALAT = 5 x UNL
- •oalkaline phosphatase = 5 x UNL
- •o(calculated) glomerular filtration rate (GFR) >50 ml/min.
- •Written informed consent must be given according to ICH/GCP, and national/local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Presence of extrahepatic disease at the time of first presentation. Patients with limited (portal) lymph node disease, patients with small (= 1 cm) extrahepatic lesions that are too small to characterize are eligible.
- •Second primary malignancy, adequately treated non-melanoma skin cancer, or other malignancy treated at least 5 years previously without evidence of recurrence.
- •Failure to prior chemotherapeutical regime for cholangiocarcinoma.
- •Known DYPD deficiency
- •Prior hepatic radiation, ablation, or resection for cholangiocarcinoma.
- •Known intolerance to gemcitabine or cisplatin.
- •Life expectancy of less than 12 weeks
- •Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Surgically related ascites does not exclude the patient.
- •(Partial) portal vein thrombosis
- •Pregnant or lactating women.
- •History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy.
- •Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
- •Organ allografts requiring immunosuppressive therapy.
- •Serious, non-healing wound, ulcer, or bone fracture.
- •Chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone equivalent excluding inhaled steroids).
- •Serious infections (uncontrolled or requiring treatment).
- •Participation in another investigational drug or participation in another interventional study.
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
研究者
相似试验
招募中
2 期
Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinomaUnresectable intrahepatic cholangiocarcinomaunresectable bileduct cancer in the liver.1001981510019818NL-OMON52590Erasmus MC, Universitair Medisch Centrum Rotterdam50
招募中
不适用
Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinomaNL-OMON23810Erasmus MC, University Medical Center40
尚未招募
2 期
Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastasescolorectal carcinoma1001799110019818NL-OMON55263Antoni van Leeuwenhoek Ziekenhuis31
进行中（未招募）
1 期
Regional chemotherapy combined with systemic chemotherapy (PUMP-IT) for potentially resectable colorectal liver metastasesPatients with potentially resectable CRLM without extrahepatic metastases with an indication for systemic therapy as induction or neoadjuvant therapy. Patients have an indication for laparotomyEUCTR2019-003260-44-NLStichting Het Nederlands Kanker Instituut-Antoni van leeuwenhoek Ziekenhuis31
尚未招募
3 期
Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy for initially unresectable colorectal liver metastases: a randomised controlled trial'Colorectal liver metastases' 'colon cancer with liver metastases'100179901001981510017991NL-OMON56934Antoni van Leeuwenhoek Ziekenhuis306